feed,title,long_url,short_url
Benzinga,ObsEva Announces Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids,https://www.benzinga.com/pressreleases/20/12/g18726944/obseva-announces-additional-phase-3-primrose-1-and-2-study-results-confirming-sustained-efficacy-a,https://j.mp/2W26CBk
Benzinga,Norsk Hydro: Capital Markets Day 2020 - Seizing opportunities where capabilities match megatrends,https://www.benzinga.com/pressreleases/20/12/g18726940/norsk-hydro-capital-markets-day-2020-seizing-opportunities-where-capabilities-match-megatrends,https://j.mp/3gwKCb8
